OZ Biosciences (OZB) is a French SME founded in 2003 that creates and develops new research tools focused on delivery technologies of bioactive materials into living organisms intended for the life sciences research world and pharmaceutical industries. The company is particularly specialized in nanotechnologies, nanoparticles bio-functionalization, formulations, transduction and transfection. The proprietary technologies of OZB are based on lipids, polymers, liposomes and magnetic nanoparticles. OZB current R&D activities are focused on the synthesis and formulations of new lipids, polymers and iron oxide magnetic nanoparticles for the delivery of various nucleic acids, proteins and other molecule, and on the bio-functionalization of nanoparticles and implantable surface, applied to neurosciences, regenerative medicine, cell therapy, vaccines, ophthalmology, ex-vivo gene therapy and cancer.
Role within SBR
OZB has developed biofunctionalized nanoparticles for various applications including 3D transfection, targeted delivery systems, Magnetofection and for promoting and enhancing viral infection. Within SBR, these technologies will serve as basis for developing biocompatible inductive inks and boosting the efficacy of AAV embedded inside the implant. OZB will contribute to SBR by engineering and developing biocompatible inductive inks and nanoparticles/AAV complexes suitable for 3D implants. OZB will synthesize biofunctionalized inductive inks and magnetic- or polymer- based nanoparticles for AAV that will be fully characterized in terms of physico-chemical properties, biocompatibilities and interaction with biological milieu. OZB will implement processes for scale up manufacturing, GLP-ready and SOP procedures to favour a rapid transition for future GMP production.